[ABT] is going to have to beat some heavyweight competitors to live up to that boast. GILD, VRTX, BMY, IDIX and others have promising hep C programs in place.
IDIX does not deserve to be mentioned in the same sentence with the others, IMO.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.